三元生物(301206) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company reported total revenue of CNY 563,363,651.68 for the current period, down from CNY 1,305,360,240.59 in the previous period, indicating a decline of approximately 56.7%[26] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in the same period last year[28] - Operating profit for Q3 2022 was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in Q3 2021[28] - The total comprehensive income for Q3 2022 was CNY 151,155,941.78, down from CNY 440,682,536.29 in the same quarter last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, total assets amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[22] - The total liabilities decreased to CNY 189,942,474.74 from CNY 588,828,870.18, a reduction of approximately 67.8%[24] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, a decrease of 82.62% year-on-year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] - Cash flow from operating activities generated a net inflow of CNY 90,426,851.62, significantly lower than CNY 520,410,877.71 in the previous year[30] - Investment activities resulted in a net cash outflow of CNY 3,282,248,061.08, compared to a smaller outflow of CNY 330,668,081.12 in the previous year[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, amounting to 92,946,000 shares[14] - The second-largest shareholder, Shandong Luxin Qisheng Investment Management Co., holds 12.25% of the shares, totaling 24,780,000 shares[14] - The company has a total of 154,353,406 restricted shares, with 2,609,206 shares released during the reporting period[17] - The company has no knowledge of any related party relationships among the top ten shareholders[15] - The company has not disclosed any information regarding the participation of the top ten shareholders in margin trading[15] - The company plans to release restricted shares on specific dates, with the earliest being February 10, 2023, for several shareholders[16] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 year-over-year[28] Certification and Auditing - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its customs clearance efficiency internationally[20] - The company changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, reflecting a strategic shift in its auditing needs[19] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, representing a reduction of approximately 76.3%[22] - Inventory levels were reported at CNY 73,203,380.23, down from CNY 112,157,402.58, indicating a decrease of about 34.7%[23] Capital Changes - The company completed a capital increase, raising its total share capital from 134,883,800 shares to 202,325,700 shares, a 49.9% increase[18] Investment Income - Investment income for the first nine months of 2022 was CNY 60,094,512.56, an increase of 85582.95% year-on-year due to interest from bank large-denomination certificates[10] - The company received CNY 850,000,000.00 from investment recoveries during the reporting period[30]